426844-50-0

Basic information

• Product Name: BOC-4,4-DIFLUORO-L-PROLINAMIDE
• Synonyms: N-T-BOC-4,4-DIFLUORO-L-PROLINAMIDE;N-T-BOC-4,4-DIFLUORO-L-PROLINE AMIDE;BOC-4,4-DIFLUORO-L-PROLINAMIDE;(S)-tert-Butyl 2-carbamoyl-4,4-difluoropyrrolidine-1-carboxylate;N-Boc-4,4-difluoro-L-prolinamide
• CAS NO: 426844-50-0
• Molecular Formula: C10H16F2N2O3
• Molecular Weight: 250.24
• Mol File: 426844-50-0.mol

Chemical Properties

• Boiling Point: 372.8°C at 760 mmHg
• Flash Point: 179.3°C
• Appearance: /
• Density: 1.26g/cm³
• Vapor Pressure: 9.37E-06mmHg at 25°C
• Refractive Index: 1.478
• Storage Temp.: 2-8°C
• PKA: 15.50±0.40(Predicted)
• CAS DataBase Reference: BOC-4,4-DIFLUORO-L-PROLINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-4,4-DIFLUORO-L-PROLINAMIDE(426844-50-0)
• EPA Substance Registry System: BOC-4,4-DIFLUORO-L-PROLINAMIDE(426844-50-0)

Safety Data

• Hazardous Substances Data: 426844-50-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BOC-4,4-DIFLUORO-L-PROLINAMIDE is used as a chiral auxiliary in the synthesis of pharmaceuticals for its ability to control the stereochemistry of reactions, which is crucial for the development of enantiomerically pure drugs with desired biological activities.
Used in Agrochemical Industry:
BOC-4,4-DIFLUORO-L-PROLINAMIDE is used as a reagent in the synthesis of agrochemicals to improve the efficiency and selectivity of the compounds, contributing to the development of more effective and environmentally friendly products.
Used in Organic Synthesis:
BOC-4,4-DIFLUORO-L-PROLINAMIDE is utilized as a chiral auxiliary in organic synthesis to facilitate the preparation of enantiomerically pure compounds, which is essential for the production of high-quality chemicals and materials with specific properties.
Used in Chemical Research and Development:
BOC-4,4-DIFLUORO-L-PROLINAMIDE is employed as a versatile tool in chemical research and development due to its stability and compatibility with a wide range of reaction conditions, enabling the exploration of new synthetic pathways and the optimization of existing processes.

InChI:InChI=1/C10H16F2N2O3/c1-9(2,3)17-8(16)14-5-10(11,12)4-6(14)7(13)15/h6H,4-5H2,1-3H3,(H2,13,15)/t6-/m0/s1

Upstream product

• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 331442-12-7 (trans)-1-[(1,1-dimethylethoxy)carbonyl]-4-hydroxy-L-proline 
• 203866-17-5 1-tert-butyl 2-methyl (2S)-4,4-difluoropyrrolidine-1,2-dicarboxylate 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 102195-80-2 (S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate 
• 203866-15-3 1-(tert-butoxycarbonyl)-4,4-difluoro-L-proline 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 796095-60-8 (2S)-1-tert-butoxycarbonyl-2-(methoxycarbonyl)-4-hydroxyazacyclopentane 

Downstream Products

• 719267-96-6 (2S)-4,4-difluoro-2-pyrrolidinecarboxamide hydrochloride 
• 1448440-48-9 (S)-tert-butyl 2-(2-carbamoyl-4,4-difluoropyrrolidin-1-yl)-2-oxoethylcarbamate 
• 1448440-50-3 tert-butyl (S)-(2-(2-cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)carbamate 
• 1448440-51-4 (S)-1-(2-aminoacetyl)-4,4-difluoropyrrolidine-2-carbonitrile hydrochloride 
• 1584652-36-7 (S)-1-(2-aminoacetyl)-4,4-difluoropyrrolidine-2-carbonitrile 4-methylbenzenesulfonic acid 
• 869489-04-3 (S)-4,4-difluoropyrrolidine-2-carbonitrile hydrochloride 

Relevant articles and documents

SPECT imaging agent for FAP-alpha specific tumor diagnosis

The invention relates to an SPECT imaging agent for FAP-alpha specific tumor diagnosis. The imaging agent is formed by taking a micromolecular FAP-alpha inhibitor of a modified N-4-quinolyl-glycine-(2S)-cyanoproline skeleton as a precursor compound, taking 99mTc as radionuclide and taking N-tris (hydroxymethyl) methylglycine (Tricine) and triphenylphosphine tri-m-sodium sulfonate (TPPTS) as synergistic ligands. Compared with the prior art, the imaging agent has high sensitivity, more excellent in-vivo biological distribution is shown, compared with the prior art, the complex has the advantagesof higher tumor uptake and tumor/organ uptake ratio, more stable coordination property, and excellent in-vivo and in-vitro stability. Due to the obvious coordination structure characteristics of theimaging agent, a one-step marking kit technology can be used, and the imaging agent has better druggability and is suitable for industrial production and clinical popularization.

INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN

Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

HEPATITIS B ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepati

DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer,

Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)

Fibroblast activation protein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV). It has been convincingly linked to multiple disease states involving remodeling of the extracellular matrix. FAP inhibition is investigated as a therapeutic option for several of these diseases, with most attention so far devoted to oncology applications. We previously discovered the N-4-quinolinoyl-Gly-(2S)-cyanoPro scaffold as a possible entry to highly potent and selective FAP inhibitors. In the present study, we explore in detail the structure-activity relationship around this core scaffold. We report extensively optimized compounds that display low nanomolar inhibitory potency and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PREP) the log D values, plasma stabilities, and microsomal stabilities of selected compounds were found to be highly satisfactory. Pharmacokinetic evaluation in mice of selected inhibitors demonstrated high oral bioavailability, plasma half-life, and the potential to selectively and completely inhibit FAP in vivo.

NOVEL FAP INHIBITORS

The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

NOVEL FAP INHIBITORS

The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

NEW COMPOUNDS

The invention relates to new compounds of the general formula (I), which are strong DPP-IV enzyme inhibitors.

PYRROLIDINE-2-CARBONITRILE DERIVATIVES AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV)

The present invention relates to compounds of formula (I), (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, b-cell failure, obesity, satiety disorders, atherosclerosis, and various immunomodulatory diseases.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, β-cell failure, obesity, satiety disorders, atherosclerosis, and various immunomodulatory diseases.